How Gadeta is bending

October 3, 2016

Utrecht – 3 October 2016

While the specificity of γδ T cells gives them the potential to treat a broader array of cancers more safely than the αβ T cell therapies in the clinic, they may not persist long enough to benefit patients because of tumor evasion mechanisms. Gadeta B.V. has created an immunotherapy strategy that combines the desirable properties of both T cell types into a single product. “We didn’t want to be another CAR T cell therapy company,” said Gadeta CEO Mark de Boer. “We wanted something to discriminate ourselves from the others.”